+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus



Statin and aspirin therapy for the prevention of cardiovascular events in patients with type 2 diabetes mellitus



Clinical Cardiology 35(12): 722-729



Patients with type 2 diabetes mellitus are at 2 to 4 times increased risk of cardiovascular events compared with those without diabetes, both among patients with multiple risk factors only and those with established atherothrombosis. In this review, we provide recommendations for the use of statins and aspirin for the prevention of cardiovascular events in high-risk patients with diabetes mellitus.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911043

Download citation: RISBibTeXText

PMID: 22760763

DOI: 10.1002/clc.22032


Related references

A comparative meta-analysis of the efficacy of statin-ezetimibe co-therapy versus statin monotherapy in reducing cardiovascular and cerebrovascular adverse events in patients with type 2 diabetes mellitus. European Review for Medical and Pharmacological Sciences 23(5): 2302-2310, 2019

Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8(): 21-21, 2007

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: 10-Year Follow-Up of a Randomized Controlled Trial. Circulation 135(7): 659-670, 2016

Usefulness of Ezetimibe Versus Evolocumab as Add-On Therapy for Secondary Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology 2019, 2019

Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong. American Journal of Cardiovascular Drugs 8(3): 199-205, 2008

Statin use reduces cardiovascular events and all-cause mortality amongst Chinese patients with type 2 diabetes mellitus: a 5-year cohort study. Bmc Cardiovascular Disorders 17(1): 166, 2018

Aspirin for the primary prevention of cardiovascular events in patients with peripheral artery disease or diabetes mellitus. Analyses from the JPAD, POPADAD and AAA trials. Thrombosis and Haemostasis 104(6): 1085-1088, 2011

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: an analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT). American Heart Journal 162(4): 748-755.E3, 2011

Atorvastatin: a review of its use in the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus. Drugs 65(1): 137-152, 2004

Intergender differences in triglyceride response to statin therapy in secondary prevention patients Diabetes mellitus type 2 patients vs non-diabetic ones. Diabetes & Metabolism 29(Hors serie 2): 4S318, 2003

Risk of new-onset diabetes mellitus versus reduction in cardiovascular events with statin therapy. American Journal of Cardiology 113(4): 631-636, 2014

Value of Coronary Computed Tomography Angiography in Tailoring Aspirin Therapy for Primary Prevention of Atherosclerotic Events in Patients at High Risk With Diabetes Mellitus. American Journal of Cardiology 117(6): 887-893, 2016

Trial of pioglitazone for the secondary prevention of cardiovascular events in patients with diabetes mellitus type 2: insufficient evidence. Nederlands Tijdschrift Voor Geneeskunde 150(7): 358-360, 2006

Statin Therapy: Diabetes Mellitus Risk and Cardiovascular Benefit in Primary Prevention. Israel Medical Association Journal 20(8): 480-485, 2018

Prediction of individual life-years gained without cardiovascular events from lipid, blood pressure, glucose, and aspirin treatment based on data of more than 500 000 patients with Type 2 diabetes mellitus. European Heart Journal 2019, 2019